Colony Group’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-3,600
Closed -$784K 799
2022
Q4
$784K Buy
+3,600
New +$786K 0.01% 534
2021
Q4
Sell
-5,319
Closed -$2.19M 806
2021
Q3
$2.19M Buy
+5,319
New +$2.21M 0.04% 305

Other funds holding CRL

Colony Group's CRL Position: Q1 2023 in Review

Colony Group sold out of Charles River Laboratories (CRL) in Q1 2023, closing a stake of 3,600 shares — an estimated $784K sold.

Colony Group first reported a position in CRL in Q3 2021 and held it in 2 quarters. The position peaked at $2.19M in Q3 2021. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

  • Colony Group reported no remaining Charles River Laboratories position as of Q1 2023 after selling out during the quarter.
  • Colony Group sold 3,600 Charles River Laboratories shares in Q1 2023, an estimated $784K.
  • Colony Group first reported a position in Charles River Laboratories in Q3 2021 and held it in 2 quarters.
  • Colony Group's Charles River Laboratories position peaked at $2.19M in Q3 2021.
  • 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Colony Group's 13F filing for Q1 2023, filed 16 May 2023.